Please login to the form below

Not currently logged in
Email:
Password:

Edelman acquires Dutch health PR firm

New York City-based Edelman has acquired the Dutch firm Hinfelaar PR, Life & Health Communications

New York City-based Edelman has acquired the Dutch firm Hinfelaar PR, Life & Health Communications, whose current clients include Boehringer Ingelheim, MerckSerono and Astellas. The agency, which is made up of seven professionals, also supports several of Edelman's healthcare clients, including AstraZeneca, Novartis, Pfizer and Wyeth.

The Dutch firm, which specialises in health and food communications, was founded in 1998 by Marc Hinfelaar, who will now join Edelman Amsterdam's management team and will lead the combined consumer, health and food teams at the Dutch offices in Amsterdam and Baarn. Before founding the company, Hinfelaar was a partner and senior consultant at the PR firm Forman Grayling B.V. and, earlier in his career, a corporate PR officer at Solvay Pharmaceuticals.

Edelman's Netherlands business, which is headquartered in Amsterdam, employs 50 professionals and has annual revenues of about €4.2m.

The purchase of Hinfelaar is the latest in a string of acquisitions for Edelman. Last month, the company acquired the Brazilian branding and PR firm Significa and the Texas-based PR firm Vollmer, whose clients include the American Heart Association and the National Multiple Sclerosis Society.

8th October 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

The ALS patient journey
Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
Equipping your medical affairs teams with solutions to navigate the healthcare landscape
Dr Tyler Ray, OPEN Health Medical Communications...
Protein degraders
Can protein degraders unlock ‘undruggable’ drug targets?
Exploring a new and exciting area of small-molecule drug discovery...

Infographics